Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Shi, Pengfei ^a   Yin, Tao ^a   Zhou, Feng ^a   Cui, Pengfei ^a   Gou, Shanmiao ^a   Wang, Chunyou ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

MICA and MICB; Natural killer cells; Pancreatic cancer; PI3KCA protein; Valproic acid

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ATM PROTEIN; ATR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; HLA A ANTIGEN; HLA B ANTIGEN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VALPROIC ACID; HLA ANTIGEN CLASS 1; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; PROTEIN KINASE B;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL SURFACE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PI3K AKT SIGNALING PATHWAY; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL; NONOBESE DIABETIC MOUSE; PANCREAS TUMOR; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR BURDEN; UP-REGULATION;

EID: 84903590719     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-370     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro RDA, Cade JE, Burley VJ, Norat T. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012, 23:843-852.
3. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259.
4. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 2012, 119:5164-5172.
5. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, Asaka M, Imamura M. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007, 21:2103-2108.
6. Balsamo M, Vermi W, Parodi M, Pietra G, Manzini C, Queirolo P, Lonardi S, Augugliaro R, Moretta A, Facchetti F, Moretta L, Mingari MC, Vitale M. Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. Eur J Immunol 2012, 42:1833-1842.
7. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H, Graham CH. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 2008, 68:4746-4753.
8. Blaheta RA, Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002, 22:492-511.
9. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo CF, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
10. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, Gopalakrishnan V. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007, 85:159-170.
11. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW, Cinatl J. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007, 96:1699-1706.
12. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005, 4:1993-2000.
13. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res 2006, 66:9245-9251.
14. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Worns M, Fischer T, Strand S, Lohse AW, Galle PR. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006, 15:227-230.
15. Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, Nakao S. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 2010, 101:609-615.
16. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias byall-trans-retinoic acid or sodium valproate. Leukemia 2009, 23:641-648.
17. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cellmediated Lysis of Myeloma. Neoplasia 2012, 14:1178-1189.
18. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 2007, 18:159-170.
19. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Natural killer cell-mediated lysis of hepatoma cells via specific induction ofNKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65:6321-6329.
20. Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ. Chimeric NKG2D CARexpressing T cell-mediated attack of human ovarian cancer isenhanced by histone deacetylase inhibition. Hum Gene Ther 2013, 24:295-305.
21. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2001, 2:443-451.
22. Lu J, Aggarwal R, Kanji S, Das M, Joseph M, Pompili V, Das H. Human ovarian tumor cells escape gammadelta T cell recognition partly by downregulating surface expression of MICA and limiting cell cycle related molecules. PLoS One 2011, 6:e23348.
23. Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R. HER2/HER3 signaling regulates NK cell mediated cytotoxicity via MHC Class IChain-Related Molecule A and B expression in human breast cancer cell lines. J Immunol 2012, 188:2136-2145.
24. Tang KF, Ren H, Cao J, Zeng GL, Xie J, Chen M, Wang L, He CX. Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol 2008, 182:233-239.
25. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-onlyprotein NOXA. Gut 2009, 58:1399-1409.
26. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloidleukemia and myelodysplasia. Blood 2010, 116:1908-1918.
27. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, Schafer BW. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and itsreactivation by HDAC inhibitors enhances combination treatment. Oncogene 2010, 29:3942-3952.
28. Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011, 28:466-474.
29. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATRdependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007, 110:606-615.
30. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
31. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surfaceexpression on malignant glioma cells. Brain 2006, 129:2416-2425.
32. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929.
33. Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005, 11:1704-1712.
34. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di GV, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foà R, Santoni A. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113:3503-3511.
35. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
36. Gao N, Cheng S, Budhraja A, Liu EH, Chen J, Chen D, Yang Z, Luo J, Shi X, Zhang Z. 3,3′-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Aktdependent process. PLoS One 2012, 7:e31783.
37. Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, Irifune K, Ito R, Miyazaki T, Okura T, Higaki J. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo. Int J Oncol 2012, 41:449-456.
38. Wang YL, Zhu BJ, Qi ZZ, Wang HJ, Zhou XD. Akt1 Enhances CA916798 Expression through mTOR Pathway. PLoS One 2013, 8:e62327.
39. Li J, Liang X, Yang X. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways. Oncol Rep 2012, 28:501-510.
40. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 2010, 16:912-923.